Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common genetic disorders, occurring in approximately 1 in every 1000 live births (Wilson, 2004). About 50% of people who inherit the mutation will develop chronic kidney disease (CKD), characterized by the development of multiple large cysts in both kidneys followed by functional decline and end-stage renal disease. While the genetic mutations in polycystin 1 and polycystin 2 (PKD1 and PKD2, respectively) (Rangan et al., 2015) were identified more than 30 years ago, the mechanism of disease development remains largely unknown (Reeders et al., 1985). Menezes et al. took an unbiased systems-biology approach to study Pkd1 gene function and report their results in the current issue of EBioMedicine (Menezes et al., 2016).

The authors performed genome wide transcript profiling on mice with conditional deletion of Pkd1, a model of ADPKD. They noted that disease severity was much milder in female mice when compared to their male counterparts. Metabolic genes represented the largest difference between control and disease (CKD) compared to healthy subjects highlighted that fatty acid metabolism is altered in human CKD samples (Kang et al., 2015). In addition, cell culture studies indicate that CKD tubule cells are unable to switch to alternative fuel source such as glucose to efficiently generate energy. When lacking in energy, tubule cells are left dedifferentiated, unable to perform energy-demanding transport functions. Results of the present study indicate that the defect in lipid metabolism is not specific for a CKD type and most likely can be seen in all forms CKD.

Future studies should aim to understand molecular alterations observed in the metabolism of CKD kidneys. Are these problems caused by a defect in a single step in fatty acid oxidation, or multiple steps are altered due to transcriptional regulatory defect? Current observations hint that the defect is upstream at the transcriptional regulation of rate limiting enzymes. Changes can be observed in critical transcription factors such as PPARA and PPARGC1a. It is likely that these upstream transcription factors balance energy generation with energy consuming cell type-specific function. This is likely achieved by transcription factor cooperativity. Future research therefore should focus on understanding the transcriptional regulatory network that controls the energetics of renal tubule cells.

To what extent do these metabolic defects contribute to the progression of ADPKD and other forms of CKD? While, Menezes et al. did not directly address the role of lipid metabolism in PKD kidneys, they did show that even a small (2%) increase in fat in animals’ diets worsened disease severity, potentially indicating that lipids play a role in ADPKD progression. The contribution of a lipid metabolism defect to other forms of CKD has already been established. Transgenic expression of PPARα or its co-activator PPARGC1a ameliorates fibrosis development induced by toxins (e.g., folic acid) or urethral obstruction, but effects...
of these manipulations have not been tested in ADPKD models. Pharmacological activation of PPARα or its upstream regulator AMPK has shown to effectively reduce scarring in mouse fibrosis models. Metformin, a widely used antidiabetic drug and pharmacological activator of AMPK, has already been shown to reduce cystogenesis in ADPKD animal model (Takiar et al., 2011), indicating commonalities in the pathway. On the other hand, these results would also indicate that activation of PPARα with fenofibrate might actually be beneficial for subjects with ADPKD. While the use of fenofibrate in the clinic is limited because it raises serum creatinine level. Clinical studies (FIELD and ACCORD) indicate that it can significantly reduce albuminuria and other intermediate CKD markers in patients with diabetes-associated CKD.

As with many new discoveries, we have more questions than answers. For example, how does mutation in membrane proteins, such as PKD1 or PKD2, result in a defect in fatty acid oxidation? What is the role of serum lipids in CKD development? Can we influence CKD development in patients by changing the fat composition of their diet?

In summary, the work by Menezes provides an excellent illustration of how unbiased high-throughput methods are able to highlight potentially targetable mechanisms in disease pathogenesis. In kidney diseases, integrated data analysis, including transcript and metabolite profiling indicate that proper fatty acid oxidation plays a critical role in CKD development.

Conflicts of interest

The Susztak lab received research support from Boehringer Ingelheim and Biogen for projects that are not related to this work.

References

Menezes, LC, Zhou, F., Germino, G., 2016. Fatty acid oxidation is impaired in an orthologous mouse model of autosomal dominant polycystic kidney disease. EbioMedicine 5, 183–192.

Kang, HM, et al., 2015. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat. Med. 21, 37–46.

Meyer, C., Nadkarni, V., Stumvoll, M., Gerich, J., 1997. Human kidney free fatty acid and glucose uptake: evidence for a renal glucose-fatty acid cycle. Am. J. Physiol. 273, E550–E554.

Rangan, G.K, Lopez-Vargas, P., Nankivell, BJ, Tchan, M., Tong, A., Turnicliffe, DJ, Savage, J., 2015. Autosomal dominant polycystic kidney disease: a path forward. Semin. Nephrol. 35, 524–537.

Reeders, S.T., Breunin, M.H., Davies, K.E., Nicholls, R.D., Jarman, A.P., Higgs, D.R., Pearson, P.L., Weatherall, D.J., 1985. A highly polymorphic DNA marker linked to adult polycystic kidney disease on chromosome 16. Nature 317, 542–544.

Rowe, I. et al., 2013. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat. Med. 19, 488–493.

Takiar, V., Nishio, S., Seo-Mayer, P., King Jr., J.D., Li, H., Zhang, L., Karihaloo, A., Halloys, K, Somlo, S., Caplan, M.J., 2011. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc. Natl. Acad. Sci. U. S. A. 108, 2462–2467.

Wilson, P.D., 2004. Polycystic kidney disease. N. Engl. J. Med. 350, 151–164.